Michael A. Gorin
Comment: The subject appears to be notable (h-index 64 in a competitive discipline) but there are too many AI signs here, which in turn has lead to a mildly gushing tone. So this needs a human to rewrite it, and to dial back the promotional language. ChrysGalley (talk) 14:15, 9 July 2026 (UTC)
| Michael A. Gorin MD | |
|---|---|
| Born | Long Island, New York, U.S. |
| 🏳️ Nationality | American |
| 💼 Occupation | |
| Known for | PSMA-targeted PET imaging; 18F-DCFPyL (piflufolastat) |
Michael A. Gorin is an American urologist, surgeon-scientist, and academic physician. He is Associate Professor of Urology and Associate Professor of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai in New York City.[1] His clinical practice is based at Mount Sinai Doctors Long Island in Greenlawn, New York, where he serves as Director of Urologic Services.[2] He specializes in the management of male voiding dysfunction resulting from benign prostatic hyperplasia, the diagnosis and treatment of early-stage prostate cancer, and complex kidney stone disease. Gorin is known for his contributions to prostate cancer diagnosis, molecular imaging of genitourinary malignancies, and the integration of artificial intelligence into urologic practice.[3][4]
Early life and education
Gorin grew up on Long Island, New York, where he attended Lynbrook High School. He received a Bachelor of Science with Distinction in Cell and Molecular Biology from the University of Michigan in 2007 before earning his Doctor of Medicine, with Distinction in Research, from the University of Miami Leonard M. Miller School of Medicine in 2011. While in medical school, he was inducted into the Alpha Omega Alpha Honor Medical Society.[5]
Following medical school, Gorin completed a general surgery internship, urology residency, and fellowship in endourology and minimally invasive surgery at the James Buchanan Brady Urological Institute at Johns Hopkins University School of Medicine, where he received advanced training in endourology, minimally invasive surgery, robotic surgery, and urologic oncology.[5][6]
Career
After completing his fellowship, Gorin joined the faculty of the Johns Hopkins University School of Medicine. He subsequently served on the voluntary faculty of the University of Pittsburgh School of Medicine before joining the Icahn School of Medicine at Mount Sinai in 2022 as Associate Professor of Urology. In 2025, he was additionally appointed Associate Professor in the Windreich Department of Artificial Intelligence and Human Health.[1]
In addition to his academic appointments, Gorin serves as Medical Director of the PeakPoint Central Nassau Surgery Center in Carle Place, New York. He played a leading role in the planning, development, and regulatory approval of the ambulatory surgery center, including navigating the New York State Certificate of Need process. The facility, which opened to patients in August 2026, was established to expand access to outpatient and minimally invasive surgical care across multiple surgical specialties for patients on Long Island.[1][7]
Clinical practice
Gorin's clinical practice focuses on diseases of the prostate and minimally invasive urologic surgery. He is among a relatively small number of urologists in the New York metropolitan area who perform holmium laser enucleation of the prostate (HoLEP), a minimally invasive procedure for the treatment of benign prostatic hyperplasia.[2][8]
His practice places particular emphasis on the diagnosis and management of early-stage prostate cancer, including prostate cancer screening, MRI-guided risk stratification, transperineal prostate biopsy, active surveillance, and focal therapy.[9][10] He has advocated for transperineal prostate biopsy as an alternative to the traditional transrectal approach and has contributed to studies evaluating its safety, diagnostic performance, and implementation into routine clinical practice.[11][12][13] He also treats complex kidney stone disease using advanced endoscopic and minimally invasive surgical techniques.
Research
Gorin is best known for his work in molecular imaging of prostate cancer. He was among the first investigators to evaluate prostate-specific membrane antigen (PSMA)-targeted PET imaging using 18F-DCFPyL (later commercialized as piflufolastat F 18, marketed as Pylarify).[14] He was involved in the design and conduct of the multicenter OSPREY and CONDOR clinical trials, which supported approval of the radiotracer by the U.S. Food and Drug Administration in 2021.[15][16][17] Piflufolastat has since become a widely used molecular imaging agent for prostate cancer staging and detection of recurrent disease.[17][18]
His research has also addressed prostate cancer screening, active surveillance, focal therapy, MRI-guided diagnosis, transperineal prostate biopsy, and renal tumor imaging.[19][9] More recently, his academic work has expanded into artificial intelligence, computer vision, and large language models for applications in clinical decision support, physician workflow, medical education, and patient care. He has contributed to the development of software tools intended to improve physician efficiency and the delivery of urologic care.[20][21] He is a named inventor on multiple U.S. patents relating to urologic and imaging technologies.[22][23][24]
According to Google Scholar, Gorin has authored more than 300 peer-reviewed publications, review articles, editorials, consensus statements, and textbook chapters, and his work has been cited more than 16,000 times.[3][4]
Editorial leadership
In 2022, Gorin was appointed Editor-in-Chief of BJUI Compass, the open-access companion journal to BJU International.[25] He has also served on the editorial boards of several international journals, including BJU International, Urologic Oncology: Seminars and Original Investigations, and the World Journal of Urology.[26][27]
Honors and awards
Gorin has received academic and clinical honors during his career, including the Drs. Carl and Barbara Alving Endowed Award for Outstanding Biomedical Research from the University of Miami Leonard M. Miller School of Medicine and the William F. Rienhoff, Jr., M.D. Scholar Award from the Johns Hopkins University School of Medicine.[5] He has been designated a Castle Connolly Top Doctor and recognized as Best Urologist in the Best of Long Island awards.[28][29]
Personal life
Gorin was raised on Long Island, New York. He is married to Heather Gorin, corporate counsel for Danfoss.[30] They have two children.
References
- ↑ 1.0 1.1 1.2 "PeakPoint Central Nassau Surgery Center". PeakPoint Central Nassau. Retrieved 8 July 2026.
- ↑ 2.0 2.1 "Dr. Michael Gorin, Urologist". U.S. News & World Report. Retrieved 8 July 2026.
- ↑ 3.0 3.1 "Michael A. Gorin". Google Scholar. Retrieved 8 July 2026.
- ↑ 4.0 4.1 "M. Gorin". Semantic Scholar. Retrieved 8 July 2026.
- ↑ 5.0 5.1 5.2 "Michael A. Gorin". ORCID. Retrieved 8 July 2026.
- ↑ "Michael A. Gorin, MD". Grand Rounds in Urology. Retrieved 8 July 2026.
- ↑ "Ownership Disclosure". PeakPoint Central Nassau. Retrieved 8 July 2026.
- ↑ "Dr. Michael Gorin, MD". Healthgrades. Retrieved 8 July 2026.
- ↑ 9.0 9.1 Mamawala, Mufaddal K.; Meyer, Alexa R.; Landis, Patricia K.; et al. (June 2020). "Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance". BJU International. 125 (6): 861–866. doi:10.1111/bju.15033. PMID 32039537 Check
|pmid=value (help). - ↑ Meyer, Alexa R.; Mamawala, Mufaddal; Winoker, Jared S.; et al. (April 2021). "Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance". The Journal of Urology. 205 (4): 1069–1074. doi:10.1097/JU.0000000000001523. PMID 33487007 Check
|pmid=value (help). - ↑ Gorin, Michael A.; Meyer, Alexa R.; Zimmerman, Matthew; et al. (2020). ""TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now". Prostate Cancer and Prostatic Diseases. 23 (1): 62–65. doi:10.1038/s41391-020-0204-8. Retrieved 8 July 2026.
- ↑ Hu, Jim C.; Assel, Melissa; Allaf, Mohamad E.; et al. (19 September 2024). "Transperineal vs Transrectal Prostate Biopsy—The PREVENT Randomized Clinical Trial". JAMA Oncology. 10 (11): 1590–1593. doi:10.1001/jamaoncol.2024.4000. PMID 39298143 Check
|pmid=value (help). - ↑ Hu, Jim C.; Assel, Melissa; Allaf, Mohamad E.; et al. (July 2024). "Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial". European Urology. 86 (1): 61–68. doi:10.1016/j.eururo.2023.12.015. PMID 38212178 Check
|pmid=value (help). - ↑ Gorin, Michael A.; Rowe, Steven P.; Patel, Hiten D.; et al. (January 2018). "Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study". The Journal of Urology. 199 (1): 126–132. doi:10.1016/j.juro.2017.07.070. PMID 28736318.
- ↑ Pienta, Kenneth J.; Gorin, Michael A.; Rowe, Steven P.; et al. (July 2021). "A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY)". The Journal of Urology. 206 (1): 52–61. doi:10.1097/JU.0000000000001698. PMID 33634707 Check
|pmid=value (help). - ↑ Morris, Michael J.; Rowe, Steven P.; Gorin, Michael A.; et al. (1 July 2021). "Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study". Clinical Cancer Research. 27 (13): 3674–3682. doi:10.1158/1078-0432.CCR-20-4573. PMID 33622706 Check
|pmid=value (help). - ↑ 17.0 17.1 Tucker, Nichole. "FDA Approves Piflufolastat for Detection of Metastasis and Recurrence in Prostate Cancer". Targeted Oncology. Retrieved 8 July 2026.
- ↑ Saperstein, Lindsay; Rowe, Steven P.; Gorin, Michael A.; et al. (August 2025). "Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B". The Prostate. 85 (11): 1005–1015. doi:10.1002/pros.24909. PMID 40320701 Check
|pmid=value (help). - ↑ Tosoian, Jeffrey J.; Mamawala, Mufaddal; Epstein, Jonathan I.; et al. (June 2020). "Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort". European Urology. 77 (6): 675–682. doi:10.1016/j.eururo.2019.12.017. PMID 31918957.
- ↑ Kaufmann, Basil; Busby, Dallin; Das, Chandan K.; et al. (March 2024). "Validation of a Zero-shot Learning Natural Language Processing Tool to Facilitate Data Abstraction for Urologic Research". European Urology Focus. 10 (2): 279–287. doi:10.1016/j.euf.2024.01.009. PMID 38278710 Check
|pmid=value (help). - ↑ Ramaswamy, Ashwin; Tyagi, Anmol; Hugo, Hunter; et al. (May 2026). "ChatGPT Health performance in a structured test of triage recommendations". Nature Medicine. 32 (5): 1671–1675. doi:10.1038/s41591-026-04297-7. PMID 41731097 Check
|pmid=value (help). - ↑ "U.S. Patent 12,570,944". Justia Patents. Retrieved 8 July 2026.
- ↑ "U.S. Patent 10,857,246". Justia Patents. Retrieved 8 July 2026.
- ↑ "U.S. Patent Application 2019/0192699". Justia Patents. Retrieved 8 July 2026.
- ↑ "BJUI Compass – Announcing the new Editor-in-Chief". BJU International. September 2022. Retrieved 8 July 2026.
- ↑ "Editorial Board – Urologic Oncology: Seminars and Original Investigations". ScienceDirect. Elsevier. Retrieved 8 July 2026.
- ↑ "Editorial Board". BJU International. Wiley. Retrieved 8 July 2026.
- ↑ "Michael A. Gorin, MD – Urology". Castle Connolly. Retrieved 8 July 2026.
- ↑ "Best Urologist on Long Island". Best of Long Island. Retrieved 8 July 2026.
- ↑ "Heather Pitofsky". LinkedIn. Retrieved 8 July 2026.
External links
References
This article "Michael Gorin" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Michael Gorin. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
